Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.

Cancer research - 15 Apr 2020

Mukhopadhyay Suman, Goswami Debanjan, Adiseshaiah Pavan P, Burgan William, Yi Ming, Guerin Theresa M, Kozlov Serguei V, Nissley Dwight V, McCormick Frank

Abstract excerpt

Pancreatic cancer is a disease with limited therapeutic options. Resistance to chemotherapies poses a significant clinical challenge for patients with pancreatic cancer and contributes to a high rate of recurrence. Oncogenic KRAS, a critical driver of pancreatic cancer, promotes metabolic reprogramming and upregulates NRF2, a master regulator of the antioxidant network. Here, we show that NRF2 contributed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gemcitabine

Share to Glutaminase

Share to Heterografts

Share to NF-E2-Related Factor 2

Share to Random Allocation

Share to Tissue Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 31911550
DOI: 10.1158/0008-5472.CAN-19-1363
PMCID: PMC7185043

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.PMID 31911550Read ↗

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.Semantic proximity Read ↗

Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming.Semantic proximity Read ↗

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read ↗

The biological role of metabolic reprogramming in pancreatic cancerSemantic proximity Read ↗

Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Energy sources identify metabolic phenotypes in pancreatic cancer.Semantic proximity Read ↗

Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levelsSemantic proximity Read ↗

Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review)Semantic proximity Read ↗

Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic TumorsSemantic proximity Read ↗

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerSemantic proximity Read ↗

The complex landscape of pancreatic cancer metabolismSemantic proximity Read ↗

Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.